Poly-L-lactic acid (PLLA) is a synthetic, biocompatible, biodegradable polymer. For soft-tissue augmentation, the size and chemical attributes of the PLLA microparticles are central to this agent's ability to promote a subclinical inflammatory response that stimulates deposition of collagen in the extracellular matrix. The resultant restoration of facial volume occurs in a controlled, predictable manner and is long lasting. The unique physiochemical and biostimulatory properties of PLLA differentiate it from other available treatments and are the foundation of the unique treatment methodology required for optimal results.
Poly-L-lactic acid (PLLA) is has been safely used in an array of clinical applications for over 30 years including dissolvable sutures, intrabone implants, and soft-tissue implants. It was first introduced as an agent for "facial filling" of lipotrophic HIV patients in 2004, 1 after having been available in Europe since 1999. In the years since its initial US approval in this difficult-to-treat population, clinical experience has led to development of treatment strategies that minimize the incidence of adverse events observed in the initial clinical trials. 2 Technical advances, coupled with an improved understanding of the contribution of volume loss to facial aging, 2 has led to the emergence of PLLA as a safe and effective treatment for the volume loss that is known to lead to a sagging or deflated appearance, 3 one of the hallmarks of facial aging. Soft-tissue augmentation is an option in facial rejuvenation that has grown considerably in popularity, as it is an efficient means to correct volume loss and is minimally invasive. 4 When assessing patients for whom revolumization with fillers is appropriate, the physiochemical properties of each treatment option should be considered to inform treatment selection. Here, the physiochemical characteristics that differentiate PLLA from hyaluronic acid (HA) fillers, as well as other biostimulatory agents such as calcium hydroxyapatite (CaHA) and polymethyl-methacrylate (PMMA), are reviewed.
When used as an injectable implant for soft-tissue volumization, PLLA is supplied as a lyophilized powder, which includes PLLA microparticles, carboxymethylcellulose, and nonpyrogenic mannitol. 5 Following reconstitution with sterile water and appropriate hydration time, the hydrocolloid suspension can be easily injected into the appropriate area.
The PLLA microparticles measure between 40 and 63 μm in diameter. This particle size ensures that the particles are large enough to avoid phagocytosis by dermal macrophages or passage through capillary walls, but small enough to be easily injected by needles as fine as 26 gauge. 6, 7 
PLLA Mechanism of Action
Once injected, the PLLA microparticles elicit a subclinical foreign body inflammatory response, resulting in encapsulation of the microparticle, followed by fibroplasia and resultant collagen type I deposition in the extracellular matrix ( Figure 1 ). 8 The course of collagen stimulation following injection with PLLA has been explored both in animal models and in human studies, 6,9-11 and preclinical studies with animal models mirror and support the findings of subsequent human studies. 9, 10 Both preclinical and human studies of tissue response to PLLA illustrate a waning inflammatory response, PLLA degradation, and collagen accumulation over time. 6 Protein adsorption occurs immediately following injection, followed by infiltration by neutrophils and then macrophages ( Figure 1 ). 8 Though an increase in volume may be visible in the patient's face immediately following injection, this is due to mechanical distention from the suspension of the microparticles and resolves within several hours to a few days. The degree of distention may be used as an approximation of how the patient will appear following ~3 treatments, allowing for a prediction of the number of treatments that will be required to achieve the desired results. 2 Within 3 weeks, the microparticles are encapsulated, and at 1 month postinjection, PLLA microparticles are surrounded by mast cells, mononuclear macrophages, foreign body cells, and lymphocytes. 9 At 3 months, the waning of the inflammatory response is indicated by the reduction in cell number. At this time, an increase in the number of collagen fibers is also apparent. 12 At 6 months, the number of macrophages and fibrocytes continues to dwindle as collagen production continues to increase. At this 6-month mark, the inflammatory response has returned to baseline. 13 Significant increases in type I collagen are observed around the periphery of the PLLA encapsulation up to between 8 and 24 months postinjection, as collagenesis continues, 6 and more recent work has demonstrated the presence of type III collagen adjacent to the PLLA particles. 11 Over the course of 9 months, the PLLA microparticles are degraded, with a 6%, 32%, and 58% reduction at 1, 3, and 6 months, respectively, and are metabolized by the same metabolic pathway as lactic acid. 9 
PLLA Physiochemical Properties
Over the last decade, an appreciation for how the physiochemical properties of all fillers, including collagen stimulators, are tied to their clinical performance has been in a state of constant evolution and refinement. The chemical properties, such as pH, charge, or affinity for water, and physical properties, such as size, shape, texture, and surface area, of the intact product (as well as its degraded form) contribute to the performance of any biomaterial. 14 With HA fillers, differing rheologic characteristics may make one product well suited for deep placement, while another may have more utility as a superficially placed "line filler."
With biostimulatory products, refinement of particle size in the development of first-to-market PMMA-based collagen stimulators represents a critically important advancement in the use of these types of agents. The initial presence of heterogeneous particle size (between 20 and 100 μm) in the first-generation Arteplast (Artes Medical, Inc., San Diego, CA) resulted in a higher degree of inflammation, leading to a higher incidence of granulomas than was desired or expected. 7 Adjustments to the manufacturing process produced a more tightly controlled particle size (25 to 40 μm), leading ultimately to the development of Artefill (Suneva Medical, Inc., San Diego, CA), a US Food and Drug Administration (FDA)-approved agent. 7 Likewise, the tightly controlled size of the PLLA microparticles (40 to 63 μm) contributes greatly to the predictability of treatment with this agent. When coupled with correct dilution, adequate hydration, and optimal injection techniques, the PLLA microparticles elicit a predictable host response and therefore a predictable cosmetic effect that may be completely controlled by the clinician. 2, 15 Additionally, proper patient selection will maximize results and decrease frustration for both the patient and the clinician (ie, fillers of any kind may be a suboptimal choice for patients with advanced skin laxity, poor craniofacial support, and high volume loss). Such patients may be better served with surgical options such as lifts, fat augmentation, and implants.
PLLA is a Unique and Long-Lasting, but not Permanent, Agent
The primary differences between HA fillers and biostimulatory agents are conceptually simple but critically important for the correct application of treatment. Though HA fillers have been shown to stimulate a comparatively small degree of collagen deposition, 16 their efficacy is based upon their ability to directly fill soft tissue, not collagen stimulation. More volumization can be obtained by using more product at any one session with this direct filling agent. In contrast, CaHA, PLLA, and PMMA are known to act through the stimulation of collagen. 10, 17 As PLLA depends exclusively on the host response to the product, rather than a direct fill, the amount of product used at any one session is determined by the surface area to be treated at that session, while the final volumetric correction is determined by the number of treatment sessions. These treatment sessions are spaced 4 to 6 weeks apart to allow time for the host response to develop between sessions.
CaHa and PLLA are durable, but ultimately biodegradable, products. The microparticles in CaHA injections are more readily degraded than those in PLLA, lasting for up to 12 to 18 months. 18 PLLA is the most durable of all currently FDA-approved biodegradable products, with results from studies used to garner initial FDA approval showing full correction still present in 80% of subjects at 24 months (the cut-off date of the original study). 5 Unlike CaHa and PLLA microparticles, PMMA is not biodegradable, making it theoretically permanent. 10 The advantages and disadvantages of this are controversial, as some clinicians express concern that permanent agents may have permanent adverse events.
PLLA as an Approach to Volume Restoration
Over recent years, a growing understanding and appreciation for the contribution of volume loss to facial aging has supported targeted use of fillers. 19 PLLA's unique mechanism of action underlies the requirement for specific treatment methodologies that are outlined below and presented in more detail elsewhere. 2, 20 High patient satisfaction has been achieved with this long-lasting approach to volume restoration. 4 PLLA provides long-lasting results exclusively through stimulation of the body's own collagen synthesis. As noted above, because the effects of PLLA collagen stimulation are not immediate, volume restoration with PLLA may require several sessions that are at least 4 weeks apart. 2 It is important to remember that the amount of PLLA injected in a single treatment is dictated by the surface area covered at that treatment session and not by the final degree of volumetric correction desired. Rather, the final degree of volumetric correction is addressed by the number of treatments. 2 A firm grasp of this concept is critical for avoiding overcorrection, especially in light of PLLA's durability.
Appropriate product reconstitution, hydration, handling, and placement are central to avoiding adverse events. Higher reconstitution volumes and longer hydration times (up to 48 hours) have been shown to reduce the risk of nodule formation. 21 Consensus recommendations further describe the procedures for optimal patient selection, product handling (including preparation and storage), and injection techniques. These consensus guidelines provide the information needed for current and best treatment practices. 20, 21 By increasing hydration time to between (24 and 48 hours) and volume to between 5 and 9 mL, as well as careful selection of the injection plane of PLLA (the uppermost portion of subcutaneous fat rather than lower dermis, and supraperiosteally), the incidence of nodules was lowered from 10%-the comparatively higher incidence reported in initial clinical studies-to 0.15%. 22, 23 
DISCUSSION
PLLA is a biocompatible, biodegradable implant that acts by stimulating a host response leading to fibroplasia, which provides volume. The widely accepted William's definition of biocompatibility is the ability of a material to perform with an appropriate host response in a specific application. 24 Therefore, the biocompatibility of this material is contingent upon the manner in which it is used (ie, how, where, and how much of the product is used may greatly influence the type and intensity of the host response). A subclinical inflammatory response followed by encapsulation and fibroplasia is the desired endpoint for application of this product as a tissue augmentation device.
In the application of tissue augmentation, a predictable response correlates with a "predictable" host (no active immunogenic issues), as well as a "predictable" amount of biomaterial (the concentration of material introduced). A predictable amount of biomaterial is easily achieved by following the guidelines outlined here in terms of preparation (dilution, hydration time) and administration (amount and level of injection). As noted above, this product is not a "passive" filler, but relies upon the host response to the product for its effect, and this is a process that takes 4 to 6 weeks. Therefore, the amount of product used at any single treatment session should be determined solely by the surface area treated at that session (using approximately 0.2 to 0.3 mL/cm 2 ), while the patient's final volumetric correction is determined by the number of treatment sessions.
It is interesting to note that our initial global experience with this product was in very wasted faces (human immunodeficiency virus-associated lipoatrophy), which required a large amount of product and many sessions to correct. Of course, very wasted faces are now recognized to need a large amount of product-any product-to correct. This early experience was also tainted by suboptimal techniques, leading to the development of an unacceptably high number of papules and nodules, a problem that resolved as a true understanding of how to use biostimulatory devices such as PLLA evolved. We now recognize that optimizing outcomes and minimizing adverse events with this product are not difficult, but simply require awareness and attention to the methodology guidelines presented herein. The subtle, natural appearing results attainable with this product have been associated with high patient satisfaction.
CONCLUSIONS
PLLA provides clinicians with a powerful tool for providing long-lasting correction of facial volume loss. As experience has been gained with this product and technical issues have evolved, it has been found to be a safe and effective product with predictable and reproducible results. Subtle, natural, and pleasing results of long duration can be obtained with a reasonable amount of product utilizing the emerging concepts of the pathophysiology of facial aging in order to optimize site-specific corrections.
Evaluate each patient individually and determine prior to the start of treatment if fillers are a cost-effective choice for the patient. Remember that very empty and very elastotic faces are very difficult to fill (regardless of product choice), requiring considerable product which may be expensive for the patient. A patient with severe global lipoatrophy and a thin body with no fat donor sites may have limited choices for rejuvenation and may therefore choose fillers regardless of cost. This may be accomplished more successfully in a patient with good skin elasticity. A patient with an outer skin envelope that is no longer able to accommodate any underlying volume loss should be made aware that replacement of volume may not give the results desired without also addressing the excess skin with a surgical lift.
As with all filler agents, less PLLA is required in younger or fuller faced patients to achieve desirable results. Treatments done over several sessions with PLLA, or even HA fillers, are appealing to many patients who prefer a slower, more subtle approach to rejuvenation. With PLLA, the patience required to go through several sessions is rewarded by the durability and longevity of the product.
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